Simeone’s group reported the potential of CEACAM1 as a serum tumor biomarker in pancreatic carcinoma and noted significantly elevated CEACAM1 had comparable specificity and sensitivity to CA19-9, a current standard serum biomarker for pancreatic cancer [13]. This evidence concerns the gene CEACAM1 and exocrine pancreatic carcinoma.